


**DISCOVER**  
**DIAGNOSE**  
**DEFEND**



Uncover the tumor's hidden biology...

# MammaPrint+Blueprint

Interrogates critical genomic pathways to metastasis & guides on therapy selection in Breast Cancer



**MammaPrint**  
FDA cleared  
and ASCO  
recommended

India's Leading Super Specialised Laboratory Network

Web: [www.oncquest.net](http://www.oncquest.net) Oncquestlaboratories

## MammaPrint + Blueprint Guide Adjuvant treatment decision making for patients with early stage Breast cancer

### MammaPrint

- FDA cleared and CE marked, recommended by ASCO for use in lymph node-positive and lymph node-negative patients.
- Clear metastatic risk stratification, no ambiguity of an 'intermediate' recurrence risk, just binary Low or High risk result.
- Result unaffected by clinico-pathological scoring.
- Supported by the highest level of clinical evidence from the landmark MINDACT trial.

### Blueprint

- Molecular subtyping into Luminal-type, HER2/neu type, and Basal-type to help inform treatment decisions.
- CE marked, has been shown to reclassify up to 22% of breast cancers compared to conventional immunohistochemistry (IHC) and fluorescence in situ hybridization(FISH) subtyping.

References: Whitworth P, et al. Ann Surg Oncol. 2014 Oct;21(10):3261-7.

### MINDACT - A unique, independent study provides the highest level of evidence to support the clinical utility of MammaPrint

#### MINDACT - Microarray in Node- Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy

- MammaPrint Low Risk patients had no statistical benefit of chemotherapy with a 94.7% five-year Distant Metastasis Free Survival (DMFS) without chemotherapy. Of 3,356 clinical high risk patients, 46% were reclassified as MammaPrint Low Risk and could avoid chemotherapy without significant compromising their outcome
- Hormone receptor positive and negative patients enrolled in the trial
- Randomized, prospective trial

References: F. Cardoso et al ; 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer - New England Journal of Medicine; August 25, 2016 vol. 375 no. 8

#### Test Details

Test Code	Test Name	Technique	Specimen	TAT / Reported on
SMO10242	MammaPrint + Blueprint Combination	Molecular Array	Formalin-fixed paraffin-embedded tissue block or 10 unstained slides with a 5 micron section on each slide. Must contain at least 30% invasive tumor.	18 working days

Regd. Office & Main Lab.: Oncquest Laboratories Ltd. 3 - Factory Road, Adjacent Safdarjung Hospital, New Delhi - 110029, Telephone.: 011-30611432, 011-30611467,  7065350350

33 laboratories, 200 Collection Centres & 1300 + Service Associates